Hemp-based health food business Elixinol Wellness has formally named Natalie Butler as its CEO having effectively led the business for the past 15 months in her role as executive director.
Butler stepped into an expanded role and joined the board in March last year following the departure of the previous CEO, Ron Dufficy.
Elixinol said Butler has been “instrumental in leading the business” since then.
“Natalie’s leadership through a complex period has been outstanding and the board has the full confidence in her ability to execute our strategic priorities,” chairman David Fenlon said.
Meanwhile, Elixinol announced the resignation of chief financial officer Josephine Lorenz0 after seven years with the company.
She has been replaced with experienced finance executive Adam Dimitropoulos who the company said brings expertise in “M&A, strategic planning, capital allocation and financial governance”.
Aurora Cannabis/MedReleaf Australia
Aurora Cannabis, the Canadian parent company of MedReleaf Australia, has posted record FY2025 results and highlighted increased international demand in markets including Australia.
The company reported a 41% year-on-year rise in international medical cannabis revenue and cited strong performance across key markets.
While it did not disclose figures for MedReleaf, Aurora said its international operations continued to deliver “strong year-over-year growth” supported by rising patient demand and market share.
Overall, Aurora’s net revenue climbed 39% to C$244.4 million (A$273.2m), adjusted EBITDA rose 261% to C$49.7 million (A$55.8m) and free cash flow turned positive at C$9.9m (A$11.1m).
The firm ended the year with C$185.3 million (A$207.9M) in cash and no cannabis-related debt.
InhaleRx
InhaleRx has received a research and development tax rebate of $402,000 for FY24, with the company expecting a further $88,000 after lodging an amended tax return for the 2023 financial year.
Funds will primarily be used for working capital, with some partially repaying amounts drawn under its $38.5 million funding facility with Clendon Biotech Capital.
Office of Drug Control
The Office of Drug Control (ODC) has begun publishing a periodic newsletter to keep companies updated on its activity.
The ODC said the aim is to “share insights, foster transparency and support our ongoing collaboration”.
To subscribe to the newsletter click here.
Tilray
Former Cannatrek executive Adam Kramer has been appointed director of Tilray Medical Australia, replacing Jonathan Trodden, who departed in May.
Kramer has held senior roles across the medicinal cannabis and broader healthcare sectors.
His appointment comes as Tilray consolidates its regional operations, having recently exited the New Zealand market, but maintaining a presence in Australia.